PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Revenue decline while Biotechnology median is 0.00%. Seth Klarman would investigate if market share loss is temporary.
-100.00%
Cost reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive advantage potential.
100.00%
Growth of 100.00% versus flat Biotechnology gross profit. Walter Schloss would verify quality.
100.00%
Margin change of 100.00% versus flat Biotechnology margins. Walter Schloss would verify quality.
7.04%
R&D growth while Biotechnology reduces spending. Peter Lynch would examine strategic differences.
-5.63%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.59%
Operating expenses growth while Biotechnology reduces costs. Peter Lynch would examine differences.
2.59%
Total costs growth while Biotechnology reduces costs. Peter Lynch would examine differences.
No Data
No Data available this quarter, please select a different quarter.
13.04%
D&A change of 13.04% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
-2.44%
EBITDA decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-2.59%
Operating income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-15.06%
Other expenses reduction while Biotechnology median is 16.53%. Seth Klarman would investigate advantages.
-3.66%
Pre-tax income decline while Biotechnology median is 1.41%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense change of 100.00% versus flat Biotechnology. Walter Schloss would verify strategy.
-10.34%
Net income decline while Biotechnology median is 2.29%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-10.26%
EPS decline while Biotechnology median is 6.25%. Seth Klarman would investigate causes.
-10.26%
Diluted EPS decline while Biotechnology median is 6.67%. Seth Klarman would investigate causes.
0.08%
Share count reduction exceeding 1.5x Biotechnology median of 0.40%. Joel Greenblatt would investigate strategy.
0.08%
Diluted share reduction exceeding 1.5x Biotechnology median of 0.37%. Joel Greenblatt would investigate strategy.